Dexelvucitabine

Dexelvucitabine (Reverset; d-d4FC), a Cytidine (HY-B0158) analog, is an orally active nucleoside reverse transcriptase inhibitor. Dexelvucitabine is a powerful agent against HIV-1-resistant viruses containing a thymidine analog and/or M184V mutation in the viral polymerase. Dexelvucitabine is a 2′-Deoxycytidine antiretroviral agent[1].

Product Specifications

CAS Number

[134379-77-4]

Product Name Alternative

Reverset; d-d4FC

UNSPSC

12352005

Hazard Statement

H315-H319

Target

HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/dexelvucitabine.html

Concentration

10mM

Purity

99.52

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N(C=C(C(N)=N1)F)[C@]2([H])O[C@@H](C=C2)CO

Molecular Formula

C9H10FN3O3

Molecular Weight

227.19

Precautions

P264-P280-P302+P352-P305+P351+P338-P362+P364

References & Citations

[1]Brenda I Hernandez-Santiago, et al. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother. 2007 Jun;51 (6) :2130-5.|[2]L Ma, et al. Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrob Agents Chemother. 1999 Feb;43 (2) :381-4.